Industry News Novo Nordisk BioSpace
Novo's CagriSema loses about 21% of body weight at lower doses in REDEFINE 9
- Phase 3 REDEFINE 9, shown at ObesityWeek, tested weekly 1 mg and 1.7 mg doses; at week 68 weight loss was about 21% and 20.7%, versus 2% on placebo, in the adherent-patient analysis.
- Counting discontinuation and rescue use, loss was 18.6% and 19.4%. Nausea and vomiting were similar to REDEFINE 1.
- The FDA obesity decision is expected in 4Q26; an 80-week REDEFINE 11 trial will probe further loss.
The lower doses roughly match the higher dose in REDEFINE 1, which suggests the top dose was not the efficiency story and could ease the tolerability burden, though nausea at 62-66% is hardly lighter. Cross-trial comparison with Lilly's tirzepatide is risky, since the earlier head-to-head failed. The next thing to check is dropout by dose, because the label dose decides how Novo prices against Zepbound.
Source: BioSpace ↗ Novo's CagriSema drives more than 20% weight loss at lower doses